Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 28, 2026
AMARIN CORP PLC\UK (AMRN)
A forensic read on AMARIN CORP PLC\UK built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
F · Poor — capital at risk
Forensic grade
Distress
Financial health
-2.1
Altman Z-score
Clean
Earnings quality
5
Forensic signals
-7.3%
ROE
$334M
Market cap
AMARIN CORP PLC\UK earns a F (Poor — capital at risk) forensic quality grade, and its Altman Z-score is -2.1, placing it in the Distress zone. 5 forensic signals were flagged in its latest SEC filings, led by inventory days.
What the filings flag
771dInventory days.Days inventory outstanding moved from 412 to 771 FY2024→FY2025 (against cost of goods sold; inventory +18% vs -37% in cost of sales). Inventory is outrunning what's being sold — a flag for softening demand or obsolescence risk ahead.
-12%Return on invested capital.Return on invested capital is -12% and rising from -20% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+1.1%/yrShare-count dilution.Diluted share count changed +3% over the last 3 years to FY2025 (+1.1%/yr). The count is GROWING — existing holders are being diluted. That's ~1.1% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~3%.
7% of revStock-based comp load.Stock-based compensation ran 7% of revenue and 207% of free cash flow in FY2025 — about $0.03 per diluted share. Heavy — a large slice of 'free cash flow' is really being paid out in stock, so the true owner cash per share is well below the headline.
217d DSOReceivables vs revenue.Days sales outstanding moved from 195 to 217 days FY2024→FY2025 (receivables +4% vs revenue -7%). Receivables are creeping up relative to sales — watch the trend.
Key fundamentals
Net Margin-18.2%
Debt / Equity0.11x
Free Cash Flow$6.5M
Latest Revenue$213.6M
Return on Equity-8.4%
Revenue Growth YoY-6.5%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on AMARIN CORP PLC\UK:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about AMRN's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown